Fifth Third Bancorp Sells 9,812 Shares of Solventum Corporation $SOLV

Fifth Third Bancorp trimmed its stake in shares of Solventum Corporation (NYSE:SOLV – Free Report) by 14.7% during the third quarter, HoldingsChannel.com reports. The firm owned 56,959 shares of the company’s stock after selling 9,812 shares during the quarter. Fifth Third Bancorp’s holdings in Solventum were worth $5,021,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in SOLV. Laurel Wealth Advisors LLC bought a new position in Solventum in the 3rd quarter worth about $29,000. JNBA Financial Advisors grew its holdings in Solventum by 71.9% during the 2nd quarter. JNBA Financial Advisors now owns 507 shares of the company’s stock valued at $39,000 after buying an additional 212 shares in the last quarter. Ameritas Advisory Services LLC purchased a new position in Solventum during the 2nd quarter valued at about $47,000. Ancora Advisors LLC bought a new stake in shares of Solventum during the second quarter valued at about $56,000. Finally, Root Financial Partners LLC bought a new stake in shares of Solventum during the third quarter valued at about $68,000.

Solventum Price Performance

Shares of NYSE SOLV opened at $86.23 on Wednesday. The firm has a market capitalization of $14.64 billion, a P/E ratio of 96.89, a P/E/G ratio of 1.26 and a beta of 0.69. The company has a quick ratio of 0.72, a current ratio of 1.03 and a debt-to-equity ratio of 0.99. The stock’s 50-day simple moving average is $87.39 and its two-hundred day simple moving average is $79.06. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $94.16.

Solventum (NYSE:SOLV – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.11. The firm had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $1.93 billion. Solventum had a return on equity of 25.03% and a net margin of 1.91%. The company’s revenue was down 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.50 EPS. As a group, equities analysts anticipate that Solventum Corporation will post 7.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SOLV has been the topic of a number of recent analyst reports. UBS Group increased their price target on shares of Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Jefferies Financial Group restated a “buy” rating on shares of Solventum in a research report on Thursday, October 8th. Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 12th. Stifel Nicolaus upped their target price on shares of Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Solventum in a report on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Solventum presently has an average rating of “Moderate Buy” and an average target price of $90.27.

Check Out Our Latest Stock Report on Solventum

Solventum Company Profile

(Free Report)

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.

Featured Stories

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.